Topiroxostat PMS

Post-marketing study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1080223727

Enrollment

3000

Registered

2017-11-22

Start date

2017-11-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout / hyperuricemia

Interventions

investigational material(s) Generic name etc : TOPILORIC Tablets, URIADEC Tablets INN of investigational material : Topiroxostat Therapeutic category code : 394 Agents for treatment of gout Dosage and

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Hyperuricemic patients with or without gout who have never used topiroxostat.

Exclusion criteria

Exclusion criteria: -

Design outcomes

Primary

Measure	Time frame
safety efficacy Safety, Efficacy	—

Countries

Japan

Contacts

Public Contact; ;

Fuji Yakuhin Co., Ltd.;SANWA KAGAKU KENKYUSHO CO.,LTD.

-;-+81-3-6811-7834;+81-52-951-8167

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026